ABSTRACT
Objetivos. En los últimos años distintas sociedades científicas y organizaciones sanitarias han generado recomendaciones orientadas a disminuir las intervenciones sanitarias que no han demostrado eficacia o efectividad. El objetivo de este estudio es evaluar el impacto de una intervención acerca de 12 recomendaciones de «no hacer» referidas al laboratorio en 7 centros hospitalarios. Métodos. Estudio antes-después llevado a cabo en 7 centros hospitalarios de Córdoba y Jaén durante los años 2015 y 2016. Se consensuaron según las recomendaciones de las sociedades científicas existentes diferentes actuaciones referidas a determinaciones de laboratorio. Se analizaron el número y coste de las determinaciones de 6 marcadores tumorales [(antígeno carcinoembrionario, antígeno prostático específico, antígeno carbohidrato (CA) 15.3, CA125, CA19.9 y alfa-fetoproteína)], tirotropina, T3, T4, hemoglobina glicada, urea, ferritina y anticuerpos antigliadina, antes y después de la implantación del consenso. Resultados. Se dejaron de hacer en el año 2016 respecto al año anterior 55.902 determinaciones de laboratorio (-19%), con un ahorro global de 82.100€. La reducción en el número de determinaciones se produjo principalmente en la urea plasmática (-50,3%) y en los marcadores tumorales CA125 (-16%), CA19.9 (-11,6%) y CA15.3 (-10,5%). El ahorro más acusado se obtuvo en la determinación de urea (-21.002€), en la de hormonas tiroideas (-12.716€) y tirotropina (-7.638€). Conclusiones. La adopción y consenso de recomendaciones de «no hacer» entre niveles asistenciales conlleva una reducción significativa de las determinaciones innecesarias (AU)
Objectives. In recent years, various scientific societies and healthcare organisations have created recommendations aimed at decreasing the use of healthcare interventions that have shown no efficacy or effectiveness. The aim of this study was to assess the impact of an intervention on 12 do-not-do recommendations regarding the laboratory in 7 hospital centres. Methods. Before-after study conducted in 7 hospital centres of Cordoba and Jaen during 2015 and 2016. Based on the recommendations of existing scientific societies, a consensus was reached on various actions regarding laboratory measurements. We analysed the number and cost of measuring 6 tumour markers (carcinoembryonic antigen, prostate-specific antigen, carbohydrate antigen [CA] 15.3, CA125, CA19.9 and alpha-fetoprotein), thyrotropin, T3, T4, glycated haemoglobin, urea, ferritin and antigliadin antibodies, before and after implementing the consensus. Results. Compared with the previous year, there were 55,902 fewer laboratory measurements (-19%) in 2016, with an overall savings of €82,100. The reduction in the number of measurements occurred mainly in plasma urea (-50.3%) and in the tumour markers CA125 (-16%), CA19.9 (-11.6%) and CA15.3 (-10.5%). The most pronounced savings were achieved in the measurements of urea (-€21,002), thyroid hormones (-€12,716) and thyrotropin (-€7,638). Conclusions. The adoption and consensus of do-not-do recommendations among healthcare levels resulted in a significant reduction in unnecessary measurements (AU)
Subject(s)
Humans , Evaluation of Results of Therapeutic Interventions/methods , Biomarkers, Tumor/economics , Patient Safety/economics , Patient Safety/standards , Laboratory Test/economics , Laboratory Test/methods , Consensus , Medical Overuse/economics , Medical Overuse/statistics & numerical dataABSTRACT
OBJECTIVES: In recent years, various scientific societies and healthcare organisations have created recommendations aimed at decreasing the use of healthcare interventions that have shown no efficacy or effectiveness. The aim of this study was to assess the impact of an intervention on 12 do-not-do recommendations regarding the laboratory in 7 hospital centres. METHODS: Before-after study conducted in 7 hospital centres of Cordoba and Jaen during 2015 and 2016. Based on the recommendations of existing scientific societies, a consensus was reached on various actions regarding laboratory measurements. We analysed the number and cost of measuring 6 tumour markers (carcinoembryonic antigen, prostate-specific antigen, carbohydrate antigen [CA] 15.3, CA125, CA19.9 and alpha-fetoprotein), thyrotropin, T3, T4, glycated haemoglobin, urea, ferritin and antigliadin antibodies, before and after implementing the consensus. RESULTS: Compared with the previous year, there were 55,902 fewer laboratory measurements (-19%) in 2016, with an overall savings of 82,100. The reduction in the number of measurements occurred mainly in plasma urea (-50.3%) and in the tumour markers CA125 (-16%), CA19.9 (-11.6%) and CA15.3 (-10.5%). The most pronounced savings were achieved in the measurements of urea (-21,002), thyroid hormones (-12,716) and thyrotropin (-7,638). CONCLUSIONS: The adoption and consensus of do-not-do recommendations among healthcare levels resulted in a significant reduction in unnecessary measurements.
